Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (8)

Showing 1-8 of 8

Sorted By:

A-Z
Z-A

Previous Next

GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy vs Standard of Care in Pts With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy vs Standard of Care in Pts With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy vs Standard of Care in Pts With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy vs Standard of Care in Pts With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
M24-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
Assess adverse events disease activity comparing IV infused ABBV-400 to LONSURF oral tablets plus IV bevacizumab in adult participants with metastatic colorectal cancer
M24-311: A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (Enrollment Paused: October 8, 2025)
Assess adverse events and change in disease activity when ABBV-400 is given in combo with Fluorouracil, Folinic Acid and Bevacizumab to adults to treat colorectal cancer
NRG-GI008: This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Phase 2/3 trial will evaluate which chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer
SGNTUC-029 (MOUNTAINEER-03): An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
If tucatinib w/ other cancer drugs works better than SOC to treat HER2 positive colorectal cancer. Also looks at side effects that happen with this combination of drugs.

Previous Next